Author: Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N
Year: 2019
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
Type of cancer: Lung
Patient population: Adult
Location: International
This is a clinical practice guideline for adults with curatively treated stage I-III non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). The guideline examines radiographic imaging and biomarker surveillance strategies for these patients. The frequency of surveillance imaging, optimal imaging modalities, patient factors that would preclude surveillance, the role of circulating biomarkers in surveillance, and the appropriateness of using magnetic resonance imaging (MRI) for NSCLC and SCLC are all specifically discussed.
AGREE II - Quality of Reporting Assessment:
Scope and purpose: 91.7%
Applicability: 54.2%
Stakeholder involvement: 77.8%
Editorial independence: 79.2%
Rigour: 76%
Clarity presentation: 91.7%
